Financial Survey: Air Products & Chemicals (APD) vs. Polydex Pharmaceuticals (POLXF)

Air Products & Chemicals (NYSE:APD) and Polydex Pharmaceuticals (OTCMKTS:POLXF) are both basic materials companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, valuation, institutional ownership, profitability and analyst recommendations.

Insider and Institutional Ownership

86.2% of Air Products & Chemicals shares are held by institutional investors. 0.4% of Air Products & Chemicals shares are held by insiders. Comparatively, 12.9% of Polydex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Air Products & Chemicals and Polydex Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Air Products & Chemicals 0 0 15 0 3.00
Polydex Pharmaceuticals 0 0 0 0 N/A

Air Products & Chemicals currently has a consensus price target of $192.17, suggesting a potential upside of 20.18%. Given Air Products & Chemicals’ higher probable upside, equities analysts plainly believe Air Products & Chemicals is more favorable than Polydex Pharmaceuticals.

Valuation and Earnings

This table compares Air Products & Chemicals and Polydex Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Air Products & Chemicals $8.93 billion 3.93 $3.00 billion $7.45 21.46
Polydex Pharmaceuticals $5.28 million 0.58 $450,000.00 N/A N/A

Air Products & Chemicals has higher revenue and earnings than Polydex Pharmaceuticals.


This table compares Air Products & Chemicals and Polydex Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Air Products & Chemicals 16.77% 15.30% 8.76%
Polydex Pharmaceuticals 8.81% 8.62% 6.76%

Volatility and Risk

Air Products & Chemicals has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, Polydex Pharmaceuticals has a beta of -0.36, meaning that its stock price is 136% less volatile than the S&P 500.


Air Products & Chemicals pays an annual dividend of $4.40 per share and has a dividend yield of 2.8%. Polydex Pharmaceuticals does not pay a dividend. Air Products & Chemicals pays out 59.1% of its earnings in the form of a dividend. Air Products & Chemicals has raised its dividend for 35 consecutive years.


Air Products & Chemicals beats Polydex Pharmaceuticals on 13 of the 15 factors compared between the two stocks.

Air Products & Chemicals Company Profile

Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, electronics and performance materials, equipment, and services worldwide. The company produces atmospheric gases, including oxygen, nitrogen, argon, and rare gases; process gases, such as hydrogen, helium, carbon dioxide, carbon monoxide, syngas, and specialty gases; and equipment for the production or processing of gases comprising air separation units and non-cryogenic generators for customers in various industries, including metals, glass, chemical processing, electronics, energy production and refining, food processing, metallurgical, medical, and general manufacturing. It also designs and manufactures equipment for air separation, hydrocarbon recovery and purification, natural gas liquefaction, and liquid helium and liquid hydrogen transport and storage. Air Products and Chemicals, Inc. was founded in 1940 and is headquartered in Allentown, Pennsylvania.

Polydex Pharmaceuticals Company Profile

Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.

Receive News & Ratings for Air Products & Chemicals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Air Products & Chemicals and related companies with's FREE daily email newsletter.

Leave a Reply